Connect Biopharma (CNTB) Competitors $0.74 -0.09 (-10.94%) Closing price 04/17/2025 03:58 PM EasternExtended Trading$0.72 -0.01 (-1.92%) As of 04/17/2025 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CNTB vs. LYEL, GLSI, IKT, PRQR, FDMT, NMRA, LRMR, NGNE, SCPH, and OGIShould you be buying Connect Biopharma stock or one of its competitors? The main competitors of Connect Biopharma include Lyell Immunopharma (LYEL), Greenwich LifeSciences (GLSI), Inhibikase Therapeutics (IKT), ProQR Therapeutics (PRQR), 4D Molecular Therapeutics (FDMT), Neumora Therapeutics (NMRA), Larimar Therapeutics (LRMR), Neurogene (NGNE), scPharmaceuticals (SCPH), and Organigram (OGI). These companies are all part of the "pharmaceutical products" industry. Connect Biopharma vs. Lyell Immunopharma Greenwich LifeSciences Inhibikase Therapeutics ProQR Therapeutics 4D Molecular Therapeutics Neumora Therapeutics Larimar Therapeutics Neurogene scPharmaceuticals Organigram Lyell Immunopharma (NASDAQ:LYEL) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, community ranking, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment. Which has better valuation & earnings, LYEL or CNTB? Connect Biopharma has higher revenue and earnings than Lyell Immunopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLyell Immunopharma$61K2,098.55-$234.63M-$1.31-0.33Connect Biopharma$24.12M1.70-$59.50MN/AN/A Does the media prefer LYEL or CNTB? In the previous week, Lyell Immunopharma had 3 more articles in the media than Connect Biopharma. MarketBeat recorded 4 mentions for Lyell Immunopharma and 1 mentions for Connect Biopharma. Lyell Immunopharma's average media sentiment score of 0.22 beat Connect Biopharma's score of -0.20 indicating that Lyell Immunopharma is being referred to more favorably in the media. Company Overall Sentiment Lyell Immunopharma Neutral Connect Biopharma Neutral Do analysts rate LYEL or CNTB? Lyell Immunopharma presently has a consensus target price of $1.00, suggesting a potential upside of 130.63%. Connect Biopharma has a consensus target price of $8.00, suggesting a potential upside of 982.25%. Given Connect Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Connect Biopharma is more favorable than Lyell Immunopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lyell Immunopharma 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50Connect Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders have more ownership in LYEL or CNTB? 66.1% of Lyell Immunopharma shares are held by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are held by institutional investors. 25.1% of Lyell Immunopharma shares are held by insiders. Comparatively, 22.6% of Connect Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is LYEL or CNTB more profitable? Connect Biopharma has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -323,792.09%. Connect Biopharma's return on equity of 0.00% beat Lyell Immunopharma's return on equity.Company Net Margins Return on Equity Return on Assets Lyell Immunopharma-323,792.09% -34.64% -30.02% Connect Biopharma N/A N/A N/A Does the MarketBeat Community prefer LYEL or CNTB? Connect Biopharma received 5 more outperform votes than Lyell Immunopharma when rated by MarketBeat users. Likewise, 73.08% of users gave Connect Biopharma an outperform vote while only 45.16% of users gave Lyell Immunopharma an outperform vote. CompanyUnderperformOutperformLyell ImmunopharmaOutperform Votes1445.16% Underperform Votes1754.84% Connect BiopharmaOutperform Votes1973.08% Underperform Votes726.92% Which has more volatility and risk, LYEL or CNTB? Lyell Immunopharma has a beta of -0.26, meaning that its stock price is 126% less volatile than the S&P 500. Comparatively, Connect Biopharma has a beta of -0.22, meaning that its stock price is 122% less volatile than the S&P 500. SummaryConnect Biopharma beats Lyell Immunopharma on 11 of the 16 factors compared between the two stocks. Get Connect Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNTB vs. The Competition Export to ExcelMetricConnect BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$40.91M$6.45B$5.30B$7.35BDividend YieldN/A3.23%5.12%4.30%P/E RatioN/A6.8921.8017.80Price / Sales1.70231.03379.9697.74Price / CashN/A65.6738.2634.64Price / Book0.405.936.443.98Net Income-$59.50M$142.99M$3.21B$247.73M7 Day Performance18.27%4.43%2.88%1.81%1 Month Performance-7.33%-12.73%-8.63%-6.98%1 Year Performance-51.37%-9.47%11.46%1.29% Connect Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNTBConnect Biopharma3.1333 of 5 stars$0.74-10.9%$8.00+982.3%-52.3%$40.91M$24.12M0.00110Short Interest ↓Gap UpLYELLyell Immunopharma3.1958 of 5 stars$0.45-3.9%$1.00+123.9%-81.8%$131.85M$61,000.00-0.57270Analyst ForecastGap DownGLSIGreenwich LifeSciences1.6036 of 5 stars$9.59+8.6%$38.00+296.2%-31.4%$126.06MN/A-11.993Earnings ReportUpcoming EarningsGap DownHigh Trading VolumeIKTInhibikase Therapeutics1.0443 of 5 stars$1.68-8.7%$6.50+286.9%-11.0%$124.90M$260,000.00-0.636PRQRProQR Therapeutics2.3805 of 5 stars$1.17-0.8%$9.50+712.0%-40.0%$123.10M$18.91M-3.66180Short Interest ↓News CoverageFDMT4D Molecular Therapeutics2.7836 of 5 stars$2.65-4.3%$26.71+908.1%-87.9%$122.70M$37,000.00-0.93120Analyst RevisionNews CoveragePositive NewsGap DownNMRANeumora Therapeutics3.1678 of 5 stars$0.75+2.3%$9.29+1,132.8%-93.8%$122.00MN/A-0.40108LRMRLarimar Therapeutics3.2364 of 5 stars$1.87-4.6%$19.63+949.5%-73.0%$119.73MN/A-1.6330Positive NewsNGNENeurogene1.9915 of 5 stars$7.86-10.6%$53.00+574.3%-65.8%$117.35M$925,000.00-1.8490Gap DownHigh Trading VolumeSCPHscPharmaceuticals3.7421 of 5 stars$2.33+0.4%$14.00+500.9%-41.9%$117.16M$36.33M-1.2330Short Interest ↓Gap DownOGIOrganigram0.566 of 5 stars$0.92-2.7%N/A-41.5%$116.74M$166.12M-2.43860 Related Companies and Tools Related Companies LYEL Competitors GLSI Competitors IKT Competitors PRQR Competitors FDMT Competitors NMRA Competitors LRMR Competitors NGNE Competitors SCPH Competitors OGI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CNTB) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | Sponsored100-year-old investment secret predicts what?!A 100-year-old indicator has quietly predicted nearly every major market meltdown — including the Dot-Com Bust...Weiss Ratings | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | Sponsored2025 could be "worse than the dot-com bust", says man who predicted 2008 banking crisisWhat's coming next to the U.S. market could be worse than anything we've ever seen before – worse than the dot...Stansberry Research | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Connect Biopharma Holdings Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Connect Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
